Novartis AG (NOVN.S)
* SANDOZ ENTERS INTO COMMERCIALIZATION AND SUPPLY AGREEMENT FOR INSULIN BIOSIMILARS, ANTICIPATING GROWING DEMAND AS DIABETES BURDEN RISES
* ANJI PHARMACEUTICALS - ANNOUNCED IT HAS LICENSED PRADIGASTAT, AN INHIBITOR OF ACYL COA: DIACYLGLYCEROL ACYL TRANSFERASE (DGAT1), FROM NOVARTIS Source text for Eikon: Further company coverage:
BRIEF-Endocyte Inc Says CFIUS Declaration Review Period With Respect To Novartis Deal Expired On Dec. 14
* ENDOCYTE INC - CFIUS DECLARATION REVIEW PERIOD WITH RESPECT TO NOVARTIS DEAL EXPIRED ON DECEMBER 14, 2018
* NOVARTIS RECEIVES EUROPEAN COMMISSION APPROVAL FOR SELF-ADMINISTRATION OF XOLAIR® ACROSS ALL INDICATIONS
Johnson & Johnson said its drug, Tremfya, was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderate-to-severe plaque psoriasis in a late-stage study.
Dec 12 Johnson & Johnson said its drug, Tremfya, was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderate-to-severe plaque psoriasis in a late-stage study.
* WE BELIEVE DATA FROM ECLIPSE TRIAL, WHICH TESTED NOVARTIS' COSENTYX AGAINST JNJ'S TREMFYA , WILL HAVE LIMITED CLINICAL RELEVANCE - NOVARTIS EXECUTIVE SAYS ON CONF. CALL
Dec 12 Johnson & Johnson said on Wednesday its drug Tremfya was more effective than a rival medicine from Novartis AG, and met the main goal of a late-stage study in adults with moderate to severe plaque psoriasis.
ZURICH/BERLIN, Dec 11 The Swiss blue-chip SMI was seen opening 1.0 percent higher at 8,634 points on Tuesday, according to premarket indications by bank Julius Baer .
Dec 6 Novartis AG said its U.S. unit Sandoz Inc will launch Adamis Pharmaceuticals Corp's emergency allergy shots next year in the United States, at a price that is about 16 percent below that of similar rival products.